Phase I, Multicenter, Open-label, ExploRatory Platform Trial to EValuate ImmunOtherapy Combinations With Chemotherapy for the Treatment of Patients With PreviousLy UnTreated MetastatIc Pancreatic AdenOcarciNoma (REVOLUTION)
Summary
The purpose of this phase I trial is to evaluate the safety and efficacy of first-line chemo-immunotherapy combinations in participants with metastatic pancreatic ductal adenocarcinoma (mPDAC).
General Information
NCT#: NCT04787991
Study ID: PICI0044
Trial Phase: Phase I
Trial Sponsor: Bristol-Myers Squibb, Parker Institute for Cancer Immunotherapy, Cancer Research Institute
Therapies Used in This Trial: Nab-paclitaxel, Gemcitabine, Ipilimumab, Hydroxychloroquine, Nivolumab